25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Renovaro Biosciences Inc
Buy, Hold or Sell?

Let's analyze Renovaro Biosciences Inc together

I guess you are interested in Renovaro Biosciences Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Renovaro Biosciences Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Renovaro Biosciences Inc

I send you an email if I find something interesting about Renovaro Biosciences Inc.

1. Quick Overview

1.1. Quick analysis of Renovaro Biosciences Inc (30 sec.)










1.2. What can you expect buying and holding a share of Renovaro Biosciences Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$0.62
Expected worth in 1 year
$0.94
How sure are you?
27.5%

+ What do you gain per year?

Total Gains per Share
$0.32
Return On Investment
22.5%

For what price can you sell your share?

Current Price per Share
$1.44
Expected price per share
$0.4731 - $1.75
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Renovaro Biosciences Inc (5 min.)




Live pricePrice per Share (EOD)
$1.44
Intrinsic Value Per Share
$-0.70 - $0.65
Total Value Per Share
$-0.08 - $1.27

2.2. Growth of Renovaro Biosciences Inc (5 min.)




Is Renovaro Biosciences Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$98m$59.6m$60m50.1%

How much money is Renovaro Biosciences Inc making?

Current yearPrevious yearGrowGrow %
Making money-$20.6m-$10.2m-$10.4m-50.3%
Net Profit Margin-6,091.4%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of Renovaro Biosciences Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Renovaro Biosciences Inc?

Welcome investor! Renovaro Biosciences Inc's management wants to use your money to grow the business. In return you get a share of Renovaro Biosciences Inc.

First you should know what it really means to hold a share of Renovaro Biosciences Inc. And how you can make/lose money.

Speculation

The Price per Share of Renovaro Biosciences Inc is $1.44. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Renovaro Biosciences Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Renovaro Biosciences Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $0.62. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Renovaro Biosciences Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.28-19.3%-0.13-9.1%-0.07-4.9%-0.09-6.2%-0.05-3.5%
Usd Book Value Change Per Share-0.44-30.9%0.085.6%-0.04-2.6%-0.02-1.6%0.021.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.44-30.9%0.085.6%-0.04-2.6%-0.02-1.6%0.021.1%
Usd Price Per Share0.48-2.01-1.75-3.42-3.61-
Price to Earnings Ratio-0.43--9.62--8.50--29.28--103.02-
Price-to-Total Gains Ratio-1.09--52.47-726.94-47.02--295.80-
Price to Book Ratio0.78-4.12-5.34-4.67--2.98-
Price-to-Total Gains Ratio-1.09--52.47-726.94-47.02--295.80-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.44
Number of shares694
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.08-0.02
Usd Total Gains Per Share0.08-0.02
Gains per Quarter (694 shares)56.12-16.20
Gains per Year (694 shares)224.49-64.80
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102242140-65-75
204494380-130-140
306736620-194-205
408988860-259-270
50112211100-324-335
60134713340-389-400
70157115580-454-465
80179617820-518-530
90202020060-583-595
100224522300-648-660

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.052.00.01.9%
Book Value Change Per Share1.02.01.025.0%3.08.01.025.0%5.014.01.025.0%11.027.02.027.5%13.036.04.024.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.053.00.0%
Total Gains per Share1.02.01.025.0%3.08.01.025.0%5.014.01.025.0%11.027.02.027.5%13.036.04.024.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Renovaro Biosciences Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.4440.081-649%-0.037-92%-0.023-95%0.016-2907%
Book Value Per Share--0.6180.754-18%0.376+64%0.796-22%0.572+8%
Current Ratio--0.0850.094-10%1.728-95%3.882-98%4.669-98%
Debt To Asset Ratio--0.1950.214-9%0.140+39%0.122+60%0.523-63%
Debt To Equity Ratio--0.2420.273-11%0.172+41%0.146+66%0.346-30%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--53182854.234288359252.168-82%270371536.262-80%532800128.624-90%596783895.752-91%
Eps---0.279-0.130-53%-0.070-75%-0.089-68%-0.050-82%
Ev To Ebitda Ratio---0.303infnan%-10.707+3438%infnan%infnan%
Ev To Sales Ratio--73.273infnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.013-0.017+30%-0.019+46%-0.022+74%-0.015+15%
Free Cash Flow To Equity Per Share--0.000-0.001+731%-0.010+12368%0.006-99%0.006-99%
Gross Profit Margin--1.0031.001+0%1.002+0%1.001+0%1.000+0%
Intrinsic Value_10Y_max--0.651--------
Intrinsic Value_10Y_min---0.698--------
Intrinsic Value_1Y_max---0.041--------
Intrinsic Value_1Y_min---0.074--------
Intrinsic Value_3Y_max---0.041--------
Intrinsic Value_3Y_min---0.221--------
Intrinsic Value_5Y_max--0.056--------
Intrinsic Value_5Y_min---0.363--------
Market Cap228552468.480+66%76707922.234319548887.918-76%277028605.762-72%542137565.424-86%572233878.240-87%
Net Profit Margin---243.654-60.914-75%--100%-12.183-95%-165.026-32%
Operating Margin---242.276-60.569-75%--100%-12.114-95%-162.481-33%
Operating Ratio--294.45173.613+300%-+100%14.723+1900%163.838+80%
Pb Ratio2.330+66%0.7824.116-81%5.342-85%4.672-83%-2.976+481%
Pe Ratio-1.292-198%-0.434-9.615+2117%-8.499+1860%-29.276+6650%-103.025+23652%
Price Per Share1.440+66%0.4832.013-76%1.745-72%3.416-86%3.605-87%
Price To Free Cash Flow Ratio-28.338-198%-9.511-28.779+203%-24.187+154%-42.348+345%-157.479+1556%
Price To Total Gains Ratio-3.241-198%-1.088-52.470+4723%726.935-100%47.020-102%-295.801+27090%
Quick Ratio--0.0580.042+37%1.321-96%3.681-98%4.512-99%
Return On Assets---0.363-0.150-59%-0.167-54%-0.136-62%-0.239-34%
Return On Equity---0.451-0.189-58%-0.207-54%-0.163-64%-0.177-61%
Total Gains Per Share---0.4440.081-649%-0.037-92%-0.023-95%0.016-2907%
Usd Book Value--98086998.000119718411.500-18%59693706.000+64%126268027.100-22%90716276.375+8%
Usd Book Value Change Per Share---0.4440.081-649%-0.037-92%-0.023-95%0.016-2907%
Usd Book Value Per Share--0.6180.754-18%0.376+64%0.796-22%0.572+8%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--53182854.234288359252.168-82%270371536.262-80%532800128.624-90%596783895.752-91%
Usd Eps---0.279-0.130-53%-0.070-75%-0.089-68%-0.050-82%
Usd Free Cash Flow---2016328.000-2620690.250+30%-2940307.750+46%-3511804.000+74%-2314725.700+15%
Usd Free Cash Flow Per Share---0.013-0.017+30%-0.019+46%-0.022+74%-0.015+15%
Usd Free Cash Flow To Equity Per Share--0.000-0.001+731%-0.010+12368%0.006-99%0.006-99%
Usd Market Cap228552468.480+66%76707922.234319548887.918-76%277028605.762-72%542137565.424-86%572233878.240-87%
Usd Price Per Share1.440+66%0.4832.013-76%1.745-72%3.416-86%3.605-87%
Usd Profit---44212036.000-20697496.250-53%-10289831.000-77%-13846509.500-69%-7707270.500-83%
Usd Revenue--181454.00045363.500+300%-+100%9072.700+1900%5611.675+3134%
Usd Total Gains Per Share---0.4440.081-649%-0.037-92%-0.023-95%0.016-2907%
 EOD+5 -3MRQTTM+13 -23YOY+13 -245Y+7 -2910Y+12 -24

3.3 Fundamental Score

Let's check the fundamental score of Renovaro Biosciences Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-1.292
Price to Book Ratio (EOD)Between0-12.330
Net Profit Margin (MRQ)Greater than0-243.654
Operating Margin (MRQ)Greater than0-242.276
Quick Ratio (MRQ)Greater than10.058
Current Ratio (MRQ)Greater than10.085
Debt to Asset Ratio (MRQ)Less than10.195
Debt to Equity Ratio (MRQ)Less than10.242
Return on Equity (MRQ)Greater than0.15-0.451
Return on Assets (MRQ)Greater than0.05-0.363
Total2/10 (20.0%)

3.4 Technical Score

Let's check the technical score of Renovaro Biosciences Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5085.393
Ma 20Greater thanMa 500.678
Ma 50Greater thanMa 1000.602
Ma 100Greater thanMa 2000.675
OpenGreater thanClose1.280
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Renovaro Biosciences Inc

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients. The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024. Renovaro Inc. is headquartered in Los Angeles, California.

Fundamental data was last updated by Penke on 2024-12-02 19:12:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is unable to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Renovaro Biosciences Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -24,365.4% means that $-243.65 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Renovaro Biosciences Inc:

  • The MRQ is -24,365.4%. The company is making a huge loss. -2
  • The TTM is -6,091.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-24,365.4%TTM-6,091.4%-18,274.1%
TTM-6,091.4%YOY--6,091.4%
TTM-6,091.4%5Y-1,218.3%-4,873.1%
5Y-1,218.3%10Y-16,502.6%+15,284.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24,365.4%-108.0%-24,257.4%
TTM-6,091.4%-218.6%-5,872.8%
YOY--210.1%+210.1%
5Y-1,218.3%-339.1%-879.2%
10Y-16,502.6%-464.5%-16,038.1%
4.3.1.2. Return on Assets

Shows how efficient Renovaro Biosciences Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • -36.3% Return on Assets means that Renovaro Biosciences Inc generated $-0.36 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Renovaro Biosciences Inc:

  • The MRQ is -36.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -15.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-36.3%TTM-15.0%-21.3%
TTM-15.0%YOY-16.7%+1.7%
TTM-15.0%5Y-13.6%-1.4%
5Y-13.6%10Y-23.9%+10.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-36.3%-11.3%-25.0%
TTM-15.0%-11.8%-3.2%
YOY-16.7%-11.3%-5.4%
5Y-13.6%-12.6%-1.0%
10Y-23.9%-14.2%-9.7%
4.3.1.3. Return on Equity

Shows how efficient Renovaro Biosciences Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • -45.1% Return on Equity means Renovaro Biosciences Inc generated $-0.45 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Renovaro Biosciences Inc:

  • The MRQ is -45.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -18.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-45.1%TTM-18.9%-26.2%
TTM-18.9%YOY-20.7%+1.8%
TTM-18.9%5Y-16.3%-2.6%
5Y-16.3%10Y-17.7%+1.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-45.1%-14.2%-30.9%
TTM-18.9%-15.9%-3.0%
YOY-20.7%-14.4%-6.3%
5Y-16.3%-18.5%+2.2%
10Y-17.7%-19.5%+1.8%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Renovaro Biosciences Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Renovaro Biosciences Inc is operating .

  • Measures how much profit Renovaro Biosciences Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • An Operating Margin of -24,227.6% means the company generated $-242.28  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Renovaro Biosciences Inc:

  • The MRQ is -24,227.6%. The company is operating very inefficient. -2
  • The TTM is -6,056.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-24,227.6%TTM-6,056.9%-18,170.7%
TTM-6,056.9%YOY--6,056.9%
TTM-6,056.9%5Y-1,211.4%-4,845.5%
5Y-1,211.4%10Y-16,248.1%+15,036.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-24,227.6%-204.6%-24,023.0%
TTM-6,056.9%-313.2%-5,743.7%
YOY--219.0%+219.0%
5Y-1,211.4%-388.9%-822.5%
10Y-16,248.1%-495.6%-15,752.5%
4.3.2.2. Operating Ratio

Measures how efficient Renovaro Biosciences Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 294.45 means that the operating costs are $294.45 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 294.451. The company is inefficient in keeping operating costs low. -1
  • The TTM is 73.613. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ294.451TTM73.613+220.838
TTM73.613YOY-+73.613
TTM73.6135Y14.723+58.890
5Y14.72310Y163.838-149.116
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ294.4512.340+292.111
TTM73.6133.187+70.426
YOY-3.282-3.282
5Y14.7234.814+9.909
10Y163.8386.494+157.344
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Renovaro Biosciences Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Renovaro Biosciences Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.08 means the company has $0.08 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.085. The company is unable to pay all its short-term debts. -2
  • The TTM is 0.094. The company is unable to pay all its short-term debts. -2
Trends
Current periodCompared to+/- 
MRQ0.085TTM0.094-0.009
TTM0.094YOY1.728-1.634
TTM0.0945Y3.882-3.788
5Y3.88210Y4.669-0.787
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0853.645-3.560
TTM0.0943.883-3.789
YOY1.7284.666-2.938
5Y3.8825.964-2.082
10Y4.6696.265-1.596
4.4.3.2. Quick Ratio

Measures if Renovaro Biosciences Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Quick Ratio of 0.06 means the company can pay off $0.06 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.058. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.042. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.058TTM0.042+0.016
TTM0.042YOY1.321-1.278
TTM0.0425Y3.681-3.639
5Y3.68110Y4.512-0.831
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0583.014-2.956
TTM0.0423.418-3.376
YOY1.3214.456-3.135
5Y3.6815.970-2.289
10Y4.5126.424-1.912
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Renovaro Biosciences Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Renovaro Biosciences Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Renovaro Biosciences Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.19 means that Renovaro Biosciences Inc assets are financed with 19.5% credit (debt) and the remaining percentage (100% - 19.5%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.195. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.214. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.195TTM0.214-0.019
TTM0.214YOY0.140+0.073
TTM0.2145Y0.122+0.092
5Y0.12210Y0.523-0.401
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1950.350-0.155
TTM0.2140.341-0.127
YOY0.1400.310-0.170
5Y0.1220.365-0.243
10Y0.5230.382+0.141
4.5.4.2. Debt to Equity Ratio

Measures if Renovaro Biosciences Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 24.2% means that company has $0.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Renovaro Biosciences Inc:

  • The MRQ is 0.242. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.273. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.242TTM0.273-0.031
TTM0.273YOY0.172+0.101
TTM0.2735Y0.146+0.127
5Y0.14610Y0.346-0.201
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2420.394-0.152
TTM0.2730.432-0.159
YOY0.1720.380-0.208
5Y0.1460.451-0.305
10Y0.3460.490-0.144
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Renovaro Biosciences Inc generates.

  • Above 15 is considered overpriced but always compare Renovaro Biosciences Inc to the Biotechnology industry mean.
  • A PE ratio of -0.43 means the investor is paying $-0.43 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Renovaro Biosciences Inc:

  • The EOD is -1.292. Based on the earnings, the company is expensive. -2
  • The MRQ is -0.434. Based on the earnings, the company is expensive. -2
  • The TTM is -9.615. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-1.292MRQ-0.434-0.859
MRQ-0.434TTM-9.615+9.182
TTM-9.615YOY-8.499-1.116
TTM-9.6155Y-29.276+19.661
5Y-29.27610Y-103.025+73.748
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-1.292-2.315+1.023
MRQ-0.434-2.491+2.057
TTM-9.615-3.156-6.459
YOY-8.499-3.274-5.225
5Y-29.276-6.037-23.239
10Y-103.025-6.785-96.240
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Renovaro Biosciences Inc:

  • The EOD is -28.338. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -9.511. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -28.779. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-28.338MRQ-9.511-18.827
MRQ-9.511TTM-28.779+19.269
TTM-28.779YOY-24.187-4.593
TTM-28.7795Y-42.348+13.569
5Y-42.34810Y-157.479+115.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-28.338-2.985-25.353
MRQ-9.511-3.361-6.150
TTM-28.779-3.734-25.045
YOY-24.187-4.557-19.630
5Y-42.348-8.327-34.021
10Y-157.479-9.311-148.168
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Renovaro Biosciences Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.78 means the investor is paying $0.78 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Renovaro Biosciences Inc:

  • The EOD is 2.330. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.782. Based on the equity, the company is cheap. +2
  • The TTM is 4.116. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.330MRQ0.782+1.548
MRQ0.782TTM4.116-3.334
TTM4.116YOY5.342-1.225
TTM4.1165Y4.672-0.555
5Y4.67210Y-2.976+7.648
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.3301.919+0.411
MRQ0.7822.051-1.269
TTM4.1162.374+1.742
YOY5.3422.454+2.888
5Y4.6723.737+0.935
10Y-2.9764.378-7.354
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Renovaro Biosciences Inc.

4.8.1. Institutions holding Renovaro Biosciences Inc

Institutions are holding 9.36% of the shares of Renovaro Biosciences Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Vanguard Group Inc3.60360.00015719603755761.339
2024-06-30BlackRock Inc2.30410.0001365695433426401063.4716
2024-09-30Geode Capital Management, LLC0.99060.00011572290-155995-9.026
2024-09-30State Street Corp0.834101323832481143.7715
2024-09-30Northern Trust Corp0.37480.000159488929141396.0251
2024-09-30Morgan Stanley - Brokerage Accounts0.22470356658-552198-60.7575
2024-09-30Charles Schwab Investment Management Inc0.1254019896600
2024-06-30Commonwealth Equity Services Inc0.0640.000310157300
2024-09-30Bank of New York Mellon Corp0.0595094386-31075-24.7687
2024-09-30JPMorgan Chase & Co0.058609301072230347.5938
2024-09-30Goldman Sachs Group Inc0.05850928853380657.2217
2024-09-30Barclays PLC0.043806953152804315.6812
2024-09-30New York State Common Retirement Fund0.04206670000
2024-09-30Nuveen Asset Management, LLC0.041806628800
2024-09-30Citigroup Inc0.038406101244570271.0741
2024-09-30HSBC Holdings PLC0.0348055191551910
2024-09-30Rhumbline Advisers0.032050756555912.2995
2024-09-30UBS Group AG0.029304645626667134.7567
2024-09-30AllianceBernstein L.P.0.023903789000
2024-06-30Jane Street Group LLC0.0226035818-20914-36.8646
Total 9.00650.000714294688+3288388+23.0%

4.9.2. Funds holding Renovaro Biosciences Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-10-31Vanguard Total Stock Mkt Idx Inv2.10560.0001334190000
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.17810.0009186982500
2024-11-27iShares Russell 2000 ETF0.79690.0011264871-2646-0.2088
2024-09-30Fidelity Small Cap Index0.31510.0009500135-264-0.0528
2024-09-30Fidelity Extended Market Index0.29970.0006475605-199474-29.5482
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.2470.000539195800
2024-11-27iShares Russell 2000 Growth ETF0.16460.001226129000
2024-10-31State St Russell Sm Cap® Indx SL Cl I0.1560.001424760000
2024-10-31Vanguard Russell 2000 ETF0.14020.001222552-1428-0.6376
2024-09-30Fidelity Total Market Index0.11650.0001184847-454-0.245
2024-11-27iShares Russell 2000 Value ETF0.10590.00071680202160.1287
2024-09-30NT R2000 Index Fund - NL0.09250.00111468211468210
2024-09-30NT Ext Equity Mkt Idx Fd - NL0.08750.00113884400
2024-09-30Northern Trust Extended Eq Market Idx0.07750.000812292700
2024-09-30NT Ext Equity Mkt Idx Fd - L0.07750.000812292700
2024-09-30NT R2000 Index Fund - DC - NL - 20.07410.00111175661175660
2024-10-31Schwab Small Cap Index0.07220.00111456700
2024-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.07050.0011118673420.3067
2024-11-27iShares Micro-Cap ETF0.06990.006811101300
2024-09-30Fidelity Series Total Market Index0.06930.0001109998-27503-20.002
Total 6.31660.022110025133+33176+0.3%

5.3. Insider Transactions

Insiders are holding 50.375% of the shares of Renovaro Biosciences Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-29Anderson Wittekind WilliamSELL11141.3
2024-07-17Anderson Wittekind WilliamSELL163621.46
2024-07-15Anderson Wittekind WilliamSELL219541.41
2024-07-11Anderson Wittekind WilliamSELL148961.51
2024-07-09Anderson Wittekind WilliamSELL46301.53
2024-07-05Anderson Wittekind WilliamSELL600001.55
2024-07-03Anderson Wittekind WilliamSELL500001.51
2024-07-01Anderson Wittekind WilliamSELL600001.56
2024-06-27Anderson Wittekind WilliamSELL146711.5
2024-06-25Anderson Wittekind WilliamSELL200001.58
2024-06-14Anderson Wittekind WilliamSELL500001.58
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. All numbers in thousands.

Summary
Total Assets121,833
Total Liabilities23,746
Total Stockholder Equity98,087
 As reported
Total Liabilities 23,746
Total Stockholder Equity+ 98,087
Total Assets = 121,833

Assets

Total Assets121,833
Total Current Assets1,948
Long-term Assets119,884
Total Current Assets
Cash And Cash Equivalents 221
Net Receivables 1,108
Inventory -439
Other Current Assets 1,242
Total Current Assets  (as reported)1,948
Total Current Assets  (calculated)2,132
+/- 184
Long-term Assets
Property Plant Equipment 1,603
Goodwill 118,171
Intangible Assets 29
Long-term Assets Other 82
Long-term Assets  (as reported)119,884
Long-term Assets  (calculated)119,884
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities23,035
Long-term Liabilities710
Total Stockholder Equity98,087
Total Current Liabilities
Short-term Debt 3,615
Accounts payable 11,402
Other Current Liabilities 8,018
Total Current Liabilities  (as reported)23,035
Total Current Liabilities  (calculated)23,035
+/-0
Long-term Liabilities
Long-term Liabilities  (as reported)710
Long-term Liabilities  (calculated)0
+/- 710
Total Stockholder Equity
Common Stock16
Retained Earnings -368,891
Accumulated Other Comprehensive Income 6,297
Other Stockholders Equity 460,665
Total Stockholder Equity (as reported)98,087
Total Stockholder Equity (calculated)98,087
+/-0
Other
Cash and Short Term Investments 221
Common Stock Shares Outstanding 156,568
Current Deferred Revenue5,805
Liabilities and Stockholders Equity 121,833
Net Debt 3,601
Net Working Capital -21,087
Short Long Term Debt Total 3,821



5.2. Balance Sheets Structured

All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-30
> Total Assets 
0
21
13
14
14
16
13
20
20
13
0
911
718
2,552
5,240
3,643
2,100
1,731
1,336
981
871
945
431
382
4,522
3,711
7,827
144,264
179,662
179,662
173,957
169,306
179,877
180,620
178,360
180,509
178,102
175,133
172,885
173,697
189,605
184,065
183,136
180,101
84,633
83,071
80,274
78,731
58,301
57,563
58,018
212,279
212,279
121,833
121,833212,279212,27958,01857,56358,30178,73180,27483,07184,633180,101183,136184,065189,605173,697172,885175,133178,102180,509178,360180,620179,877169,306173,957179,662179,662144,2647,8273,7114,5223824319458719811,3361,7312,1003,6435,2402,55271891101320201316141413210
   > Total Current Assets 
0
21
13
14
14
16
13
20
20
13
0
560
423
2,345
5,046
3,476
1,900
1,568
1,193
835
732
785
282
235
4,199
3,161
7,238
17,065
15,762
15,762
13,269
10,507
12,495
11,209
9,063
11,266
8,941
6,066
4,008
4,921
20,899
15,455
14,619
11,696
9,565
8,133
5,389
3,927
2,565
1,906
2,403
1,220
1,220
1,948
1,9481,2201,2202,4031,9062,5653,9275,3898,1339,56511,69614,61915,45520,8994,9214,0086,0668,94111,2669,06311,20912,49510,50713,26915,76215,76217,0657,2383,1614,1992352827857328351,1931,5681,9003,4765,0462,34542356001320201316141413210
       Cash And Cash Equivalents 
0
12
0
0
0
2
0
7
7
0
0
54
181
598
3,009
3,435
400
1,048
531
151
23
32
118
34
3,942
2,945
2,306
17,018
15,601
15,601
13,240
10,272
12,282
11,138
8,627
10,939
8,696
5,966
3,425
4,526
20,664
15,377
13,708
11,151
9,172
7,972
4,119
2,948
1,874
523
244
313
313
221
2213133132445231,8742,9484,1197,9729,17211,15113,70815,37720,6644,5263,4255,9668,69610,9398,62711,13812,28210,27213,24015,60115,60117,0182,3062,9453,9423411832231515311,0484003,4353,00959818154007702000120
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
424
147
1,709
2,030
0
0
0
0
0
0
0
0
0
0
0
4,812
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000004,812000000000002,0301,70914742400000000000
       Net Receivables 
0
8
13
13
13
13
13
13
13
13
8
70
85
35
8
41
400
460
582
644
695
746
155
194
224
181
105
31
123
123
3
2
21
15
3
0
2
2
0
0
2
2
0
0
0
0
0
0
0
1,058
1,074
0
0
1,108
1,108001,0741,058000000022002203152123123123311051812241941557466956445824604004183585708131313131313131380
       Other Current Assets 
0
0
0
0
0
0
0
0
0
0
0
436
156
1,712
2,030
0
0
60
80
40
14
6
9
7
33
36
4,827
15
38
38
26
232
192
56
434
326
243
100
583
395
233
78
911
545
393
161
1,271
979
691
325
1,086
907
907
1,242
1,2429079071,0863256919791,2711613935459117823339558310024332643456192232263838154,827363379614408060002,0301,71215643600000000000
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
352
296
207
194
167
200
163
143
145
138
160
149
148
323
550
589
127,199
163,873
163,900
160,688
158,799
167,382
169,411
169,297
169,244
169,161
169,068
168,877
168,776
168,706
168,610
168,518
168,405
75,068
74,938
74,884
74,804
55,735
55,656
55,615
211,059
211,059
119,884
119,884211,059211,05955,61555,65655,73574,80474,88474,93875,068168,405168,518168,610168,706168,776168,877169,068169,161169,244169,297169,411167,382158,799160,688163,900163,873127,19958955032314814916013814514316320016719420729635200000000000
       Property Plant Equipment 
0
0
0
0
0
0
0
0
0
0
0
40
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
29
27
27
655
744
688
2,720
2,611
2,563
2,482
2,389
2,307
2,213
2,155
2,064
1,967
1,869
1,744
1,622
1,569
1,493
1,423
1,346
1,310
1,875
1,875
1,603
1,6031,8751,8751,3101,3461,4231,4931,5691,6221,7441,8691,9672,0642,1552,2132,3072,3892,4822,5632,6112,7206887446552727290000000000000004000000000000
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
67
67
0
0
0
0
0
0
0
0
25
25
25
0
0
11
0
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
11,640
164,187
164,187
118,171
118,171164,187164,18711,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,64011,6400110025252500000000676700000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
196
422
447
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000000000000447422196000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
234
220
199
186
161
200
160
140
143
136
133
122
120
124
125
123
127,138
152,095
152,095
148,255
146,278
154,917
154,913
154,908
154,903
154,901
154,901
154,900
154,893
154,890
154,885
154,879
154,875
61,615
61,611
61,613
61,612
42,651
42,649
42,644
44,976
44,976
29
2944,97644,97642,64442,64942,65161,61261,61361,61161,615154,875154,879154,885154,890154,893154,900154,901154,901154,903154,908154,913154,917146,278148,255152,095152,095127,13812312512412012213313614314016020016118619922023400000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3
153
3
9
34
138
138
138
138
138
138
0
138
138
138
30
30
21
21
0
22
0
65
62
0
22
0
0
0
0
0
00000220626502202121303013813813801381381381381381383493153300000000000000000000000
> Total Liabilities 
0
19
23
27
27
47
55
71
71
84
79
3,098
3,349
4,933
1,758
972
1,000
1,014
894
1,044
1,508
1,743
1,715
1,988
2,989
951
5,974
906
23,765
23,765
25,239
25,337
6,777
8,438
7,077
10,286
11,830
10,903
10,945
11,379
14,942
17,090
17,517
18,858
12,014
12,746
875
12,603
11,799
10,816
14,423
43,684
43,684
23,746
23,74643,68443,68414,42310,81611,79912,60387512,74612,01418,85817,51717,09014,94211,37910,94510,90311,83010,2867,0778,4386,77725,33725,23923,76523,7659065,9749512,9891,9881,7151,7431,5081,0448941,0141,0009721,7584,9333,3493,098798471715547272723190
   > Total Current Liabilities 
0
19
23
27
27
47
55
71
71
84
79
3,098
3,349
4,933
1,758
972
1,000
1,014
894
1,044
1,508
1,410
1,405
1,988
2,989
951
5,974
906
874
874
1,638
1,519
1,110
1,301
1,090
971
1,335
832
1,559
1,408
1,886
1,211
6,202
7,512
6,451
7,159
875
11,773
11,023
10,096
13,758
20,874
20,874
23,035
23,03520,87420,87413,75810,09611,02311,7738757,1596,4517,5126,2021,2111,8861,4081,5598321,3359711,0901,3011,1101,5191,6388748749065,9749512,9891,9881,4051,4101,5081,0448941,0141,0009721,7584,9333,3493,098798471715547272723190
       Short-term Debt 
0
14
5
5
5
9
55
64
64
74
77
1,705
1,717
1,611
100
99
0
101
101
103
103
103
103
440
2,090
496
209
0
0
0
0
0
0
256
261
266
271
276
282
287
292
298
5,031
6,281
1,454
1,399
4,929
6,207
4,818
3,877
6,727
0
8,086
3,615
3,6158,08606,7273,8774,8186,2074,9291,3991,4546,2815,0312982922872822762712662612560000002094962,0904401031031031031011010991001,6111,7171,70577746464559555140
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
336
1,607
408
447
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,728
6,002
1,200
1,200
4,726
6,001
4,625
3,663
6,509
7,119
0
0
007,1196,5093,6634,6256,0014,7261,2001,2006,0024,7280000000000000004474081,60733600000000000000000000000
       Accounts payable 
0
5
0
0
0
0
0
0
0
0
41
568
669
624
924
823
0
893
623
795
1,185
1,077
1,065
1,228
670
445
934
899
874
807
754
1,270
539
610
628
328
593
282
189
505
321
548
167
487
1,402
4,683
4,555
4,471
5,297
5,421
5,578
7,991
7,991
11,402
11,4027,9917,9915,5785,4215,2974,4714,5554,6831,4024871675483215051892825933286286105391,2707548078748999344456701,2281,0651,0771,1857956238930823924624669568410000000050
       Other Current Liabilities 
0
0
17
22
22
38
0
7
7
10
2
824
964
2,699
734
50
0
20
169
147
220
230
238
320
230
11
4,831
7
0
67
884
249
572
435
201
377
471
273
1,088
616
1,273
365
1,004
744
3,595
1,078
1,808
501
185
798
1,453
1,526
4,798
8,018
8,0184,7981,5261,4537981855011,8081,0783,5957441,0043651,2736161,08827347137720143557224988467074,83111230320238230220147169200507342,6999648242107703822221700
   > Long-term Liabilities 
0
0
5
0
5
9
55
0
64
74
77
2,273
2,385
2,235
1,024
922
0
994
725
897
1,288
333
310
1,668
2,760
941
1,143
899
22,891
22,891
23,601
23,818
5,667
7,137
5,987
9,315
10,495
10,071
9,386
9,971
13,056
15,879
11,315
11,346
5,563
5,587
2,082
829
776
721
664
22,810
22,810
710
71022,81022,8106647217768292,0825,5875,56311,34611,31515,87913,0569,9719,38610,07110,4959,3155,9877,1375,66723,81823,60122,89122,8918991,1439412,7601,6683103331,28889772599409221,0242,2352,3852,273777464055950500
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
230
221
0
0
0
0
0
0
0
0
0
0
0
0
5,707
5,781
5,855
5,929
5,705
0
5,853
1,200
0
0
0
4,652
0
0
0
0
0
0
0
00000004,6520001,2005,85305,7055,9295,8555,7815,707000000000000221230000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
22,891
21,423
23,601
23,818
5,667
5,399
4,317
2,007
3,182
2,755
2,069
2,952
6,038
8,863
9,030
10,311
0
0
0
0
0
0
0
0
0
0
000000000010,3119,0308,8636,0382,9522,0692,7553,1822,0074,3175,3995,66723,81823,60121,42322,8910000000000000000000000000000
> Total Stockholder Equity
0
2
-9
-14
-14
-32
-42
-51
-51
-71
-79
-2,186
-2,631
-2,381
3,482
2,671
0
717
442
-63
-637
-798
-1,284
-1,606
1,533
2,760
1,853
143,358
155,898
155,898
148,717
143,969
173,100
172,182
171,283
170,223
166,272
164,230
161,941
162,319
174,663
166,975
165,619
161,243
72,619
70,325
66,899
66,128
46,502
46,746
43,596
168,596
168,596
98,087
98,087168,596168,59643,59646,74646,50266,12866,89970,32572,619161,243165,619166,975174,663162,319161,941164,230166,272170,223171,283172,182173,100143,969148,717155,898155,898143,3581,8532,7601,533-1,606-1,284-798-637-6344271702,6713,482-2,381-2,631-2,186-79-71-51-51-42-32-14-14-920
   Common Stock
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
1
1
1
1
1
1
1
1
1
1
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
5
5
5
6
6
6
6
7
7
0
15
16
16150776666555555555555544444111111111101111111111111110
   Retained Earnings Total Equity000000-220,831-212,04500-114,108-107,907-101,3240-73,549-69,518-66,585-64,188-60,090-58,576-56,855-52,772-62,596-57,890-39,899-37,595-32,706-29,746-28,669-28,444-28,259-28,012-27,094-26,301-25,545-25,338-24,9160-23,145-21,892-20,939-20,404-19,947-10400000000-230
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
-28
-16
200
275
718
1,000
534
680
383
564
539
943
835
353
98
-32
-268
-234
206
339
199
102
-177
-46
-56
-41
-13
-3
-13
-11
-15
-19
-21
-30
-38
-30
-32
-30
-64
-27
0
1,034
6,297
6,2971,0340-27-64-30-32-30-38-30-21-19-15-11-13-3-13-41-56-46-177102199339206-234-268-32983538359435395643836805341,000718275200-16-2800000000000
   Capital Surplus 
0
25
0
0
0
0
0
0
0
0
25
17,788
17,788
18,357
25,098
25,098
0
25,098
25,098
25,098
25,098
25,756
25,785
25,816
29,622
31,330
31,629
176,329
193,284
193,370
206,265
206,362
225,765
229,209
229,899
230,364
230,497
230,823
231,457
235,876
0
268,308
273,540
275,367
0
0
282,402
286,986
0
0
0
0
0
0
000000286,986282,40200275,367273,540268,3080235,876231,457230,823230,497230,364229,899229,209225,765206,362206,265193,370193,284176,32931,62931,33029,62225,81625,78525,75625,09825,09825,09825,098025,09825,09818,35717,78817,7882500000000250
   Treasury Stock000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
25
25
25
25
25
25
25
25
25
17,788
17,788
18,357
25,098
25,098
0
25,098
25,098
25,098
25,098
25,756
25,785
25,816
29,872
31,330
31,629
176,329
206
193,284
206,265
206,362
225,765
229,209
229,899
230,364
230,497
230,823
231,457
235,876
265,580
268,308
273,540
275,367
276,989
282,402
283,427
286,986
290,555
300,008
301,349
0
442,305
460,665
460,665442,3050301,349300,008290,555286,986283,427282,402276,989275,367273,540268,308265,580235,876231,457230,823230,497230,364229,899229,209225,765206,362206,265193,284206176,32931,62931,33029,87225,81625,78525,75625,09825,09825,09825,098025,09825,09818,35717,78817,78825252525252525252500



5.3. Balance Sheets

All numbers in thousands.




5.4. Cash Flows

All numbers in thousands.